BidaskClub downgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a buy rating to a hold rating in a research report report published on Thursday, December 7th.
Other analysts have also recently issued reports about the company. Stifel Nicolaus restated a buy rating and issued a $70.00 price objective (up from $60.00) on shares of Esperion Therapeutics in a research report on Thursday, August 10th. Zacks Investment Research upgraded Esperion Therapeutics from a sell rating to a hold rating in a research report on Wednesday, August 23rd. Jefferies Group reiterated a buy rating and set a $85.00 price target on shares of Esperion Therapeutics in a research report on Monday, August 21st. Bank of America reiterated a neutral rating and set a $60.00 price target on shares of Esperion Therapeutics in a research report on Friday, August 11th. Finally, Chardan Capital boosted their price objective on Esperion Therapeutics from $20.00 to $75.00 and gave the stock a neutral rating in a research note on Wednesday, December 6th. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and an average target price of $60.85.
Esperion Therapeutics (NASDAQ:ESPR) traded up $0.66 during trading on Thursday, hitting $66.50. The company had a trading volume of 437,181 shares, compared to its average volume of 578,390. Esperion Therapeutics has a 12-month low of $10.71 and a 12-month high of $68.60. The firm has a market capitalization of $1,710.00, a P/E ratio of -9.69 and a beta of 2.73.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the prior year, the business earned ($0.77) earnings per share. equities analysts expect that Esperion Therapeutics will post -7.3 earnings per share for the current fiscal year.
In related news, Director Nicole Vitullo sold 9,326 shares of the stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total transaction of $502,205.10. Following the transaction, the director now owns 2,472 shares of the company’s stock, valued at approximately $133,117.20. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 32.50% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its holdings in Esperion Therapeutics by 69,371.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 4,856 shares during the period. Aperio Group LLC purchased a new stake in Esperion Therapeutics during the 2nd quarter worth about $249,000. SG Americas Securities LLC increased its holdings in shares of Esperion Therapeutics by 74.5% in the 2nd quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 2,991 shares during the last quarter. Voya Investment Management LLC increased its holdings in shares of Esperion Therapeutics by 12.7% in the 2nd quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 806 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY purchased a new position in shares of Esperion Therapeutics in the 1st quarter valued at about $385,000. Institutional investors own 92.24% of the company’s stock.
WARNING: “BidaskClub Lowers Esperion Therapeutics (NASDAQ:ESPR) to Hold” was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.truebluetribune.com/2018/01/03/esperion-therapeutics-espr-stock-rating-lowered-by-bidaskclub.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.